Skip to content
Blog
5 min readBy Peptid AI EditorialEditorial policy

KPV: A Tracking Guide for the Anti-Inflammatory Tripeptide

How to log KPV use across gut, skin, and inflammatory endpoints without overclaiming.

At a glance

What it is
α-MSH C-terminal tripeptide (Lys-Pro-Val)
Route
Oral, SC, or topical
Frequency
Daily
Typical cycle
Several weeks
First effects
Weeks

KPV is one of the smallest peptides people experiment with. Three amino acids: lysine, proline, valine. It is the C-terminal tripeptide of alpha-MSH, and most of the interest in it comes from preclinical and early clinical work on anti-inflammatory signaling.

What it does

KPV appears to act on inflammatory pathways through mechanisms that overlap with alpha-MSH but without the pigmentation effects. Research has explored its activity in inflammatory bowel disease models, skin inflammation, and antimicrobial contexts. The clinical evidence in humans is limited, and most enthusiasm comes from animal data and case reports.

It is most often discussed in three contexts: oral or enteric-coated capsules for gut applications, topical use for skin, and subcutaneous injection as a general anti-inflammatory.

Typical protocol shape

Oral KPV for gut applications is typically run daily for a defined window of several weeks. Subcutaneous protocols are usually daily as well. Topical formulations are used once or twice daily over the affected area. Specific dose ranges vary widely in the literature and the gray market.

What to track daily

  • Time, route, dose, and site
  • For gut users: stool frequency, Bristol score, abdominal pain on a 1 to 10 scale, bloating, urgency
  • For skin users: photos of affected area in consistent lighting, itch score
  • For systemic anti-inflammatory use: target joint or symptom score
  • Sleep quality
  • Any nausea, flushing, or injection-site reaction

What to track weekly

  • Average symptom score for your primary endpoint
  • Body weight
  • Any dietary changes or trigger-food incidents
  • For IBD-context users: blood in stool, fatigue, frequency of flares

Bloodwork worth doing

  • hs-CRP and ESR for inflammation
  • CBC and CMP for safety
  • For gut users: fecal calprotectin is a more sensitive marker than serum inflammation
  • Baseline and follow-up at the same lab to control for assay variation

Realistic expectations

KPV is one of the peptides where, if it works for you, it tends to work within weeks rather than days, and the change is usually a reduction in symptom severity rather than complete resolution. For users with mild inflammatory complaints it can be subtle. For users with active disease, it is not a substitute for prescribed therapy.

Common mistakes

  • Treating an undiagnosed gut problem with KPV instead of getting it worked up
  • Changing diet and starting KPV in the same week, which makes attribution impossible
  • Using a non-enteric capsule and expecting gut-localized effects
  • Stopping prescribed medication without medical guidance
  • Running it indefinitely without a planned reassessment

A tracking template

Per dose: timestamp, route, dose. Per day: target symptom score, secondary symptoms, sleep, any side effects. Per week: average score, weight, photo if relevant. Per cycle: hs-CRP, fecal calprotectin if applicable, CBC and CMP. Peptid AI will graph your daily score against your dose timing, which is the simplest way to see whether the curve is actually bending.

Safety notes

KPV has a relatively benign profile in available data, but "limited human data" cuts both ways. Use it as an experiment, not a substitute for diagnosis, and let your clinician know what you are doing if you have an inflammatory condition.

On legal status: KPV is one of the peptides caught up in the FDA's 2026 compounding review. Alongside BPC-157, TB-500, and MOTS-C, it is scheduled for evaluation at the Pharmacy Compounding Advisory Committee meeting on July 23-24, 2026, which will weigh whether these peptides belong on the 503A compounding list. Until that resolves, availability through compounding pharmacies is uncertain and the research-chemical supply is unregulated - assume the label may be wrong.

Peptid AI is an educational and self-tracking tool. Nothing in this post is medical advice. Doses mentioned reflect what is commonly reported in research literature — they are not recommendations. Always consult a qualified physician before starting, changing, or stopping any protocol.

Atlas entry

KPV — half-life, route and cautions

1 h · Subcutaneous

Build my plan Takes 2 minutes